Overexpression of the chimeric plasmin-resistant VEGF165/VEGF183 (132-158) protein in murine breast cancer induces distinct vascular patterning adjacent to tumors and retarded tumor growth Corrigendum in /mmr/11/5/4010

Zhang,Hui-Yong; Fan,Bing-Lin; Wu,Xin-Sheng; Mu,Ling‑Min; Wang,Wen-Feng; Zhu,Wu-Ling

doi:10.3892/mmr.2014.2866

Overexpression of the chimeric plasmin-resistant VEGF165/VEGF183 (132-158) protein in murine breast cancer induces distinct vascular patterning adjacent to tumors and retarded tumor growth

Corrigendum in: /mmr/11/5/4010

Authors:
- Hui-Yong Zhang
- Bing-Lin Fan
- Xin-Sheng Wu
- Ling‑Min Mu
- Wen-Feng Wang
- Wu-Ling Zhu
View Affiliations

Affiliations: College of Life Science and Biotechnology, Xinxiang Medical University, Xinxiang, Henan 453003, P.R. China, School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, Henan 453003, P.R. China, Department of Vasculocardiology, Xinxiang 371 Central Hospital, Xinxiang, Henan 453003, P.R. China
Published online on: November 5, 2014 https://doi.org/10.3892/mmr.2014.2866
Pages: 1483-1489

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A chimeric plasmin‑resistant vascular endothelial growth factor (VEGF)165/VEGF192 (132-158) protein, named as VEGF192 (according to the nomenclature of VEGF), designed by a previous study, was demonstrated to have an enhanced affinity for the extracellular matrix (ECM) amongst other bioactivities. However, it is now accepted that mutant VEGFs frequently demonstrate different angiogenic activities and produce different vascular patterning from the parental molecule. The present study hypothesized that VEGF192, due to its enhanced binding affinity to the ECM, would exhibit a different angiogenic activity and produce a different vascular patterning compared to those of VEGF165. Murine breast cancer EMT‑6 cells were manipulated to stably overexpress VEGF165 or VEGF192. These cells were then inoculated intradermally into BALB/c mice in order to monitor the formation of vascular patterning in skin proximal to tumors. In vivo angiogenesis experiments revealed that overexpression of VEGF192 in murine breast cancer cells resulted in irregular, disorganized and dense vascular patterning as well as induced a significant inhibition of tumor growth compared with that of VEGF165. In addition, allograft tumor immunochemical assays of VEGF192‑overexpressing tumors demonstrated significantly lower vascular densities than those of VEGF165‑overexpressing tumors; however, VEGF192 tumors had a significantly enlarged vascular caliber. Conversely, cell wound healing experiments revealed that VEGF192‑overexpressing EMT‑6 cells had significantly decreased migration rates compared with those of VEGF165‑overexpressing EMT‑6 cells. In conclusion, the results of the present study supported the hypothesis that the altered ECM affinity of VEGF induced structural alterations to vasculature. In addition, these results provided a novel insight into VEGF design and indirect evidence for the function of exon 8 in VEGF.

View Figures

View References

1	Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT and De Bruijn EA: Vascular endothelial growth factor and angiogenesis. Pharmacol Rev. 56:549–580. 2004. View Article : Google Scholar : PubMed/NCBI
2	Carmeliet P: Angiogenesis in life, disease and medicine. Nature. 438:932–936. 2005. View Article : Google Scholar : PubMed/NCBI
3	Lee RJ, Springer ML, Blanco-Bose WE, Shaw R, Ursell PC and Blau HM: VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation. 102:898–901. 2000. View Article : Google Scholar : PubMed/NCBI
4	Hariawala MD, Horowitz JR, Esakof D, et al: VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts. J Surg Res. 63:77–82. 1996. View Article : Google Scholar : PubMed/NCBI
5	Simons M: Angiogenesis: where do we stand now? Circulation. 111:1556–1566. 2005. View Article : Google Scholar : PubMed/NCBI
6	Huiyong Z, Yong L, Yunxiao S, Wuling Z, Jingjing L and Taiming L: Generation of a chimeric plasmin-resistant VEGF165/VEGF183 (132–158) protein and its comparative activity. Protein Pept Lett. 20:947–954. 2013. View Article : Google Scholar : PubMed/NCBI
7	Robinson CJ and Stringer SE: The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci. 114(Pt 5): 853–865. 2001.PubMed/NCBI
8	Tammela T, He Y, Lyytikkä J, et al: Distinct architecture of lymphatic vessels induced by chimeric vascular endothelial growth factor-C/vascular endothelial growth factor heparin-binding domain fusion proteins. Circ Res. 100:1468–1475. 2007. View Article : Google Scholar : PubMed/NCBI
9	Simons M: Silky, sticky chimeras-designer VEGFs display their wares. Circ Res. 100:1402–1404. 2007. View Article : Google Scholar : PubMed/NCBI
10	Keskitalo S, Tammela T, Lyytikkä J, et al: Enhanced capillary formation stimulated by a chimeric vascular endothelial growth factor/vascular endothelial growth factor-C silk domain fusion protein. Circ Res. 100:1460–1467. 2007. View Article : Google Scholar : PubMed/NCBI
11	Zheng Y, Watanabe M, Kuraishi T, Hattori S, Kai C and Shibuya M: Chimeric VEGF-ENZ7/PlGF specifically binding to VEGFR-2 accelerates skin wound healing via enhancement of neovascularization. Arterioscler Thromb Vasc Biol. 27:503–511. 2007. View Article : Google Scholar
12	Lee S, Jilani SM, Nikolova GV, Carpizo D and Iruela-Arispe ML: Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol. 169:681–691. 2005. View Article : Google Scholar : PubMed/NCBI
13	Lauer G, Sollberg S, Cole M, Krieg T and Eming SA: Generation of a novel proteolysis resistant vascular endothelial growth factor165 variant by a site-directed mutation at the plasmin sensitive cleavage site. FEBS Lett. 531:309–313. 2002. View Article : Google Scholar : PubMed/NCBI
14	Suhonen KA, Anttila MA, Sillanpää SM, Hämäläinen KM, Saarikoski SV, Juhola M and Kosma VM: Quantification of angiogenesis by the Chalkley method and its prognostic significance in epithelial ovarian cancer. Eur J Cancer. 43:1300–1307. 2007. View Article : Google Scholar : PubMed/NCBI
15	Grunstein J, Masbad JJ, Hickey R, Giordano F and Johnson RS: Isoforms of vascular endothelial growth factor act in a coordinate fashion to recruit and expand tumor vasculature. Mol Cell Biol. 20:7282–7291. 2000. View Article : Google Scholar : PubMed/NCBI
16	Mineur P, Colige AC, Deroanne CF, et al: Newly identified biologically active and proteolysis-resistant VEGF-A isoform VEGF111 is induced by genotoxic agents. J Cell Biol. 179:1261–1273. 2007. View Article : Google Scholar : PubMed/NCBI
17	Ferrara N: Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol. 29:789–791. 2009. View Article : Google Scholar : PubMed/NCBI
18	Carmeliet P, Ng YS, Nuyens D, et al: Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat Med. 5:495–502. 1999. View Article : Google Scholar : PubMed/NCBI
19	Ruhrberg C, Gerhardt H, Golding M, et al: Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. Genes Dev. 16:2684–2698. 2002. View Article : Google Scholar : PubMed/NCBI
20	Maes C, Stockmans I, Moermans K, et al: Soluble VEGF isoforms are essential for establishing epiphyseal vascularization and regulating chondrocyte development and survival. J Clin Invest. 113:188–199. 2004. View Article : Google Scholar : PubMed/NCBI
21	Ferrara N: Binding to the extracellular matrix and proteolytic processing: two key mechanisms regulating vascular endothelial growth factor action. Mol Biol Cell. 21:687–690. 2010. View Article : Google Scholar : PubMed/NCBI
22	Stalmans I, Ng YS, Rohan R, et al: Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. J Clin Invest. 109:327–336. 2002. View Article : Google Scholar : PubMed/NCBI
23	Schoeffner DJ, Matheny SL, Akahane T, et al: VEGF contributes to mammary tumor growth in transgenic mice through paracrine and autocrine mechanisms. Lab Invest. 85:608–623. 2005. View Article : Google Scholar : PubMed/NCBI
24	Soker S, Takashima S, Miao HQ, Neufeld G and Klagsbrun M: Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell. 92:735–745. 1998. View Article : Google Scholar : PubMed/NCBI
25	Mercurio AM, Lipscomb EA and Bachelder RE: Non-angiogenic functions of VEGF in breast cancer. J Mammary Gland Biol Neoplasia. 10:283–290. 2005. View Article : Google Scholar
26	Hervé MA, Buteau-Lozano H, Vassy R, et al: Overexpression of vascular endothelial growth factor 189 in breast cancer cells leads to delayed tumor uptake with dilated intratumoral vessels. Am J Pathol. 172:167–178. 2008. View Article : Google Scholar :
27	Jia H, Jezequel S, Löhr M, et al: Peptides encoded by exon 6 of VEGF inhibit endothelial cell biological responses and angiogenesis induced by VEGF. Biochem Biophys Res Commun. 283:164–173. 2001. View Article : Google Scholar : PubMed/NCBI
28	Hervé MA, Buteau-Lozano H, Mourah S, Calvo F and Perrot-Applanat M: VEGF189 stimulates endothelial cells proliferation and migration in vitro and up-regulates the expression of Flk-1/KDR mRNA. Exp Cell Res. 309:24–31. 2005. View Article : Google Scholar : PubMed/NCBI
29	Chen TT, Luque A, Lee S, Anderson SM, Segura T and Iruela-Arispe ML: Anchorage of VEGF to the extracellular matrix conveys differential signaling responses to endothelial cells. J Cell Biol. 188:595–609. 2010. View Article : Google Scholar : PubMed/NCBI